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AITL

:   angioimmunoblastic T‐cell lymphoma

ALK^−^ ALCL

:   ALK‐negative ALCL

ALK^+^ ALCL

:   ALK‐positive anaplastic large cell lymphoma

ALK

:   anaplastic lymphoma kinase

ANKL

:   aggressive NK‐cell leukemia

ATLL

:   adult T‐cell leukemia/lymphoma

CI

:   confidence interval

CM

:   cytotoxic molecule

CTL

:   cytotoxic T lymphocyte

EATL

:   enteropathy‐associated T‐cell lymphoma

EBV

:   Epstein‐Barr virus

ENKL

:   extranodal NK/T‐cell lymphoma, nasal type

FFPE

:   formalin‐fixed, paraffin‐embedded

GrB

:   granzyme B

IHC

:   immunohistochemistry

IPI

:   International Prognostic Index

LILRB1

:   leukocyte immunoglobulin‐like receptor subfamily B member 1

MEITL

:   monomorphic epitheliotropic intestinal T‐cell lymphoma

NA

:   not available

NK

:   natural killer

NKR

:   NK‐cell receptor

OS

:   overall survival

PD‐1

:   programmed cell death‐1

PTCL‐NOS, PTCL

:   not otherwise specified

PTCL

:   peripheral T‐cell lymphoma

PTNKL

:   peripheral T‐ or NK‐cell lymphomas

TCR

:   T‐cell receptor

TFH

:   follicular helper T cell

WHO

:   World Health Organization

1. INTRODUCTION {#cas13512-sec-0001}
===============

Peripheral T‐ or NK‐cell lymphomas are a group of rare diseases.[1](#cas13512-bib-0001){ref-type="ref"} Although they account for 15%‐20% of aggressive lymphomas in Western countries,[2](#cas13512-bib-0002){ref-type="ref"} the number is higher in Japan, accounting for 30%‐40% of aggressive lymphomas.[2](#cas13512-bib-0002){ref-type="ref"}, [3](#cas13512-bib-0003){ref-type="ref"} The differences are explained by the high incidence of HTLV‐I‐associated ATLL and EBV‐associated ENKL.[2](#cas13512-bib-0002){ref-type="ref"}, [3](#cas13512-bib-0003){ref-type="ref"} Although the current WHO classification includes more than 25 disease entities in PTNKL, making a correct diagnosis per se has a prognostic impact on clinical outcome.[1](#cas13512-bib-0001){ref-type="ref"}, [2](#cas13512-bib-0002){ref-type="ref"} With increased understanding of PTNKL, subtype‐specific approaches have shown to achieve a promising therapeutic effect, particularly in ENKL.[4](#cas13512-bib-0004){ref-type="ref"} Although ATLL is defined as the HTLV‐I‐harboring CD4^+^ T‐cell neoplasm, ENKL is composed of EBV‐harboring CM‐positive neoplasms of different cell lineages including αβT cells, γδT cells and NK cells.[1](#cas13512-bib-0001){ref-type="ref"}, [2](#cas13512-bib-0002){ref-type="ref"}, [5](#cas13512-bib-0005){ref-type="ref"} Recent observation showed the existence of EBV‐harboring CTL‐type PTCL mimicking ENKL.[6](#cas13512-bib-0006){ref-type="ref"} These cases raise concerns regarding differences in the cell of origin between ENKL and EBV‐harboring PTCL‐NOS.

NK‐cell receptors found in mature NK cells contribute to positive or negative signaling during NK‐cell‐mediated cytotoxicity. Activating NKR including DNAM1 (CD226), NKG2D (CD314), and a natural cytotoxicity receptor such as NKp46 (CD335) recognize alterations of cell surface molecules on virus‐infected cells and tumor cells.[7](#cas13512-bib-0007){ref-type="ref"} Binding of the activating NKR to ligands induces the activated NK cells to attack their targets.[7](#cas13512-bib-0007){ref-type="ref"} In contrast, inhibitory NKR including CD94‐NKG2A and LILRB1 (also known as ILT2/MIR7/CD85j) bind to human leukocyte antigen class I molecules and prevent the NK cells from killing healthy cells.[7](#cas13512-bib-0007){ref-type="ref"} However, the expressions of NKR are shown not only in NK cells, but also in unconventional innate‐like T cells comprising γδT cells, invariant NKT cells, mucosal‐associated invariant T cells, and intestinal intraepithelial lymphocytes.[8](#cas13512-bib-0008){ref-type="ref"}, [9](#cas13512-bib-0009){ref-type="ref"} They play a role in the preservation of tissue integrity and span the innate‐adoptive continuum.[8](#cas13512-bib-0008){ref-type="ref"}, [9](#cas13512-bib-0009){ref-type="ref"}

Previous studies showed that CD94, NKG2A, and NKp46 were usually detected in ENKL, whereas the expression of another group of NKR, the killer cell immunoglobulin‐like receptors seem to be reduced in most ENKL cases.[10](#cas13512-bib-0010){ref-type="ref"}, [11](#cas13512-bib-0011){ref-type="ref"}, [12](#cas13512-bib-0012){ref-type="ref"} The pathological implication of NKR in PTNKL remains to be defined. Therefore, we examined the expressions of LILRB1, DNAM1, NKp46, and NKG2D in several PTNKL entities and carried out a clinicopathological study.

2. MATERIALS AND METHODS {#cas13512-sec-0002}
========================

2.1. Case selection and clinical data collection {#cas13512-sec-0003}
------------------------------------------------

Selected aggressive PTNKL cases were consecutively diagnosed at St. Marianna University Hospital (Kawasaki, Japan) between January 2011 and October 2016. All cases were diagnosed according to the current WHO classification.[1](#cas13512-bib-0001){ref-type="ref"} In this study, PTCL‐NOS were further categorized into 3 groups: i.e, TFH‐type PTCL, CTL‐type PTCL, and others. TFH‐type PTCL was defined as nonspecific T‐cell lymphomas showing CD4^+^TIA‐1^−^ phenotype and expressing at least two TFH‐associated antigens including PD‐1, CD10, Bcl‐6, and CXCL13.[1](#cas13512-bib-0001){ref-type="ref"} In contrast, CTL‐type PTCL was defined as nonspecific T‐cell lymphoma showing TIA‐1^+^GrB^+^ phenotype. We also collected clinical data including age, sex, initial sites of involvement, clinical stage according to the Cotswolds‐modified Ann Arbor staging system, IPI, mode of initial therapy, duration of follow up, and status at time of last follow up in each case. Informed consent was obtained from all surviving patients prior to being included in the study. This protocol was approved by the Institutional Review Boards of the St. Marianna University School of Medicine.

2.2. Immunohistochemistry {#cas13512-sec-0004}
-------------------------

Immunohistochemistry was carried out on sections of FFPE tissues. In addition to our PTNKL diagnostic panel (the first set: CD3, CD4, CD5, CD8, CM including TIA‐1 and GrB, *EBER* in situ hybridization; the second set: CD30, CD56, PD‐1, Bcl‐6 and ALK), we assessed the expression profile of TCRβ, TCRδ, LILRB1, DNAM1, NKp46, and NKG2D, which are available for IHC. Heat‐induced antigen retrieval (120°C, 6 min) was carried out using 10 mM citrate buffer, pH 6 (DAKO Japan, Tokyo, Japan). Primary antibodies used were anti‐TCRβ mouse monoclonal antibody (G‐11) (Santa Cruz Biotechnology, Dallas, TX, USA), anti‐TCRδ (H‐41) mouse monoclonal antibody (Santa Cruz Biotechnology), anti‐LILRB1 rabbit monoclonal antibody (Abcam, Cambridge, UK), anti‐CD226 rabbit polyclonal antibody (Sigma‐Aldrich Japan, Tokyo, Japan), anti‐NKP46/NCT1 goat polyclonal antibody (R&D Systems, Minneapolis, MN, USA), and anti‐NKG2D goat polyclonal antibody N‐20 (Santa Cruz Biotechnology). All stains were interpreted as follows: negative, no staining; −/+, equivocal staining but definite positivity in \<30% of presumptive neoplastic cells; +/−, definite positivity in 30%‐70% of presumptive neoplastic cells; +, definite positivity in ≥70% of presumptive neoplastic cells.

2.3. PCR‐based TCR gene rearrangement analyses {#cas13512-sec-0005}
----------------------------------------------

Genomic DNA was extracted from FFPE tissue using the ReliaPrep™ FFPE gDNA Miniprep System (Promega, Madison, WI, USA). PCR was carried out according to the BIOMED‐2 protocols.[11](#cas13512-bib-0011){ref-type="ref"} We initially assessed TCRγ gene (*TRG*) rearrangement. In cases without monoclonal *TRG* bands, TCRβ gene (*TRB*) rearrangements were also analyzed.[13](#cas13512-bib-0013){ref-type="ref"}

2.4. Statistical analysis {#cas13512-sec-0006}
-------------------------

Survival curves were determined using the Kaplan‐Meier method, and the difference was compared using the log‐rank test. All analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University, ver.1.33).[14](#cas13512-bib-0014){ref-type="ref"} All *P*‐values were two‐tailed, and *P* \< .05 was considered significant.

3. RESULTS {#cas13512-sec-0007}
==========

3.1. Diagnosis of PTNKL {#cas13512-sec-0008}
-----------------------

Between January 2011 and October 2016, a total of 291 cases were diagnosed with malignant lymphomas at our institution. Among them, 22 cases (7.6%) were found to have PTNKL. According to the current WHO classification,[1](#cas13512-bib-0001){ref-type="ref"} they were diagnosed with AITL in two, ALK^+^ ALCL in two, ALK^−^ ALCL in two, ENKL in three, MEITL in three, ANKL in one, and PTCL‐NOS in nine. Nine PTCL‐NOS cases were further regarded as TFH‐type PTCL (5 cases), CTL‐type PTCL (3 cases), and others (true PTCL‐NOS) (1 case). Clinicopathological features of the cases are shown in Table [1](#cas13512-tbl-0001){ref-type="table-wrap"}. TCRδ was detected in CM‐positive lymphoma cases only including one ALK^−^ ALCL, one EBV‐positive CTL‐type PTCL, and one MEITL case (UPN \#10, \#18, and \#19, respectively) (Table [1](#cas13512-tbl-0001){ref-type="table-wrap"}). TCRβ was evaluated in CM‐positive lymphoma cases only because of the limited amount of residual specimens. Because the frequencies and intensities of stained lymphoma cells were relatively low, the positive cases included one EBV‐positive CTL‐type PTCL and two MEITL cases (UPN \#17, \#20, and \#21, respectively) (Table [1](#cas13512-tbl-0001){ref-type="table-wrap"}). Therefore, we considered 3 cases (UPN \#10, \#18, and \#19) as a γδT‐cell lymphoma. Indeed, we detected neither TCRδ nor TCRβ in both ALK^+^ ALCL cases. Except for 3 cases (UPN \#13, \#14, and \#22), monoclonal *TRG* bands were detected in the remaining 19 cases. We confirmed that these cases are T‐cell lymphomas. The remaining 3 cases also showed polyclonal *TRB* bands only, indicating that they are true NK‐cell neoplasms.

###### 

Clinicopathological features of 22 examined cases

  UPN   Age/Sex   Diagnosis     Primary site   Clinical stage   IPI score   Immunophenotype   NK receptor   TCRβ   TCRδ   *TRG* GR   Initial therapy   Survival (days)                                                                                                                            
  ----- --------- ------------- -------------- ---------------- ----------- ----------------- ------------- ------ ------ ---------- ----------------- ----------------- ----- ----- ---- ----- ----- ---- ----- ----- ----- ------------------------------------------ ------------------------- ---------------------------------------------
  1     79/F      AITL          LN             III              3           \+                \+            \+     −      −          NA                \+                −     −     −    −/+   −     −    −     NA    −     m                                          THP‐COP                   1043[a](#cas13512-note-0005){ref-type="fn"}
  2     67/F      AITL          LN             IV               3           \+                \+            \+     −      −/+        NA                \+                −     −     −    \+    −     −    −     NA    −     m                                          None                      17
  3     61/F      PTCL (TFH)    LN             III              2           \+                +/−           \+     −      −          −                 −                 −     −     −    +/−   −     −    −     NA    −     m                                          CHOP                      751[a](#cas13512-note-0005){ref-type="fn"}
  4     63/M      PTCL (TFH)    LN             III              3           \+                \+            \+     −      +/−        NA                −                 −/+   −     −    −/+   −     −    −     NA    −     m                                          CHOP                      852[a](#cas13512-note-0005){ref-type="fn"}
  5     82/F      PTCL (TFH)    LN             III              3           \+                \+            +/−    −      +/−        NA                \+                −     −     −    +/−   −     −    −     NA    −     m                                          THP‐COP                   1089[a](#cas13512-note-0005){ref-type="fn"}
  6     68/M      PTCL (TFH)    LN             IV               3           \+                \+            \+     −      −          NA                \+                −/+   −     −    \+    −     −    −     NA    −     m                                          EPOCH                     570[a](#cas13512-note-0005){ref-type="fn"}
  7     65/M      PTCL (TFH)    LN             III              3           \+                \+            \+     −      −          NA                \+                −     −     −    +/−   −     −    −     NA    −     m                                          EPOCH                     933[a](#cas13512-note-0005){ref-type="fn"}
  8     21/M      ALK^+^ ALCL   LN             II               0           −                 −/+           −      −      \+         −                 NA                \+    −     −    −     −     −    −     −     −     m                                          CHOP                      174[a](#cas13512-note-0005){ref-type="fn"}
  9     62M       ALK^+^ ALCL   GI tract       IV               3           −                 +/−           −      −      \+         −                 NA                \+    \+    −    \+    +/−   −    −/+   −     −     m                                          CHOP                      890
  10    69/M      ALK^−^ ALCL   GI tract       II               3           \+                −             \+     −      \+         −                 NA                \+    −     −    \+    −     −    −/+   −     \+    m                                          DEX                       107
  11    49/M      ALK^−^ ALCL   LN             IV               2           \+                \+            \+     −      \+         −                 NA                −     −     −    −     \+    −    −     −/+   −     m                                          EPOCH                     574[a](#cas13512-note-0005){ref-type="fn"}
  12    56/M      PTCL‐NOS      GI tract       IV               2           \+                −             −      −      −          −                 NA                −     −     −    −     −     −    −/+   NA    −     m                                          CHOP                      330
  13    56/M      ENKL          Nasal cavity   I                1           −                 −             −      −      NA         \+                NA                \+    \+    \+   −/+   −     \+   \+    −     −     p[a](#cas13512-note-0005){ref-type="fn"}   CHOP                      598
  14    61/M      ENKL          Nasal cavity   II               2           +/−               −             −      +/−    NA         \+                NA                \+    +/−   \+   +/−   \+    \+   −/+   −     −     p[a](#cas13512-note-0005){ref-type="fn"}   SMILE                     1788[a](#cas13512-note-0005){ref-type="fn"}
  15    64/M      ENKL          Nasal cavity   I                2           \+                −             −      −/+    NA         \+                NA                \+    \+    \+   \+    \+    \+   −/+   −/+   −     m                                          MILD                      1291[a](#cas13512-note-0005){ref-type="fn"}
  16    68/M      PTCL (CTL)    SC tissue      IV               4           \+                −             +/−    +/−    −          −                 NA                \+    \+    \+   −     −     −    −     −/+   −     m                                          DEX                       50
  17    72/F      PTCL (CTL)    GI tract       II               5           \+                −             −      \+     −          −−                NA                +/−   \+    \+   −     −     \+   −     +/−   −     m                                          DEX+[l]{.smallcaps}‐Asp   120
  18    73/M      PTCL (CTL)    LN             IV               4           \+                −             −      \+     −          −                 NA                \+    \+    \+   \+    \+    \+   \+    −     +/−   m                                          THP‐COP                   35
  19    53/M      MEITL         Intestine      II               2           \+                −             −      −      −          \+                NA                \+    −     −    \+    −     \+   \+    −     +/−   m                                          CHOP                      860
  20    57/M      MEITL         Intestine      IV               2           +/−               −             −      \+     −          \+                NA                \+    \+    −    +/−   +/−   \+   −     +/−   −     m                                          NA                        38[a](#cas13512-note-0005){ref-type="fn"}
  21    71/M      MEITL         Intestine      IV               4           \+                −             −      \+     −          −                 NA                \+    −/+   −    \+    −     \+   \+    +/−   −     m                                          None                      134
  22    72M       ANKL          BM             IV               4           +/−               −             −      −      NA         \+                NA                \+    +/−   \+   \+    +/−   \+   \+    −     −     p[b](#cas13512-note-0006){ref-type="fn"}   MILD                      184

+, ≥70% positive; +/−, ≥30%\~70% positive; −/+, \~30% positive; −, no staining.

AITL, angioimmunoblastic T‐cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ANKL, aggressive NK‐cell leukemia; BM, bone marrow; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; DEX, dexamethasone; ENKL, extranodal NK/T‐cell lymphoma, nasal type; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin; GI, gastrointestinal; GR, gene rearrangement; ICE, ifosfamide, carboplatin, and etoposide; IPI, international prognostic index; [l]{.smallcaps}‐Asp, [l]{.smallcaps}‐asparaginase; LILRB1, leukocyte immunoglobulin‐like receptor subfamily B member 1; LN, lymph node; m, monoclonal; MEITL, monomorphic epitheliotropic intestinal T‐cell lymphoma; MILD, methotrexate, ifosfamide, [l]{.smallcaps}‐asparaginase, and dexamethasone; NA, not available; NOS, not otherwise specified; p, polyclonal; PTCL, peripheral T‐cell lymphoma; SC, subcutaneous; SMILE, dexamethasone, methotrexate, ifosfamide, [l]{.smallcaps}‐asparaginase, and etoposide; TFH, follicular helper T cell; THP‐COP, pirarubicin, cyclophosphamide, vincristine, and prednisolone; UPN, unique patient number.

Alive at the last observation point.

*TRB* gene rearranged band was also undetected.

John Wiley & Sons, Ltd

3.2. NKR expression in PTNKL {#cas13512-sec-0009}
----------------------------

Representative cases are presented in Figure [1](#cas13512-fig-0001){ref-type="fig"}. A total of 14 cases (64%) were positive for LILRB1 (Table [1](#cas13512-tbl-0001){ref-type="table-wrap"}). This molecule was expressed regardless of the disease entity. The expression was shown in ANKL (1/1, 100%), ENKL (2/3, 67%), CTL‐type PTCL (1/3, 33%), MEITL (3/3, 100%), ALK^+^ ALCL (1/2, 50%), ALK^−^ ALCL (1/2, 50%), TFH‐type PTCL (4/5, 80%), and AITL (1/2, 50%). In contrast, activating NKR, DNAM1, NKp46, and NKG2D were detected mainly in TIA‐1‐positive neoplasms (46%, 69%, and 38%, respectively). Expression of DNAM1 was shown in ANKL (1/1, 100%), ENKL (2/3, 67%), CTL‐type PTCL (1/3, 33%), MEITL (1/3, 33%), ALK^+^ ALCL (1/2, 50%), and ALK^−^ ALCL (1/2, 50%). This molecule was also detected in the reticuloendothelial cells surrounding neoplastic cells (Figure [2](#cas13512-fig-0002){ref-type="fig"}). Expression of NKp46 was shown in ANKL (1/1, 100%), ENKL (3/3, 100%), CTL‐type PTCL (2/3, 67%), and MEITL (3/3, 100%). Furthermore, NKG2D was also expressed in ANKL (1/1, 100%), ENKL (1/3, 33%), CTL‐type PTCL (1/3, 33%) and MEITL (2/3, 67%). Compared with the staining pattern of DNAM1, these molecules were detected exclusively in neoplastic cells. Although the expression trend in NKG2D was similar to that in NKp46, the positive rate was lower than that of NKp46. One EBV‐harboring CTL‐type PTCL case (UPN \#16) lacked the expression of all examined NKR in spite of the extranodal disease presentation (Figure [1](#cas13512-fig-0001){ref-type="fig"}F).

![Expression of natural killer (NK) cell receptors (NKR) in peripheral T‐ or NK‐cell lymphomas. Each biopsy specimen was morphologically assessed using hematoxylin and eosin (HE) staining and immunohistochemistry. A, Angioimmunoblastic T‐cell lymphoma (AITL) case (unique patient number \[UPN\] \#2). This case showed expression of inhibitory NKR leukocyte immunoglobulin‐like receptor subfamily B member 1 (LILRB1). B, Follicular helper T‐cell (TFH)‐type peripheral T‐cell lymphoma (PTCL) case (UPN \#4). This case also expressed LILRB1. C, Anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) case (UPN \#8). This case was negative for any NKR whereas NKp46 was detected in the bystander cells. D, ALK‐negative ALCL case (UPN \#10). This case expressed only LILRB1. E, Extranodal NK/T‐cell lymphoma, nasal type (ENKL) case (UPN \#14). This case was an NK‐cell‐derived lymphoma and showed expression of LILRB1 and activating NKR DNAM1 and NKp46, whereas NKG2D was not detected in the lymphoma cells. F, CTL‐type PTCL case (UPN \#16). Although this case mimics ENKL because of the positivity of Epstein‐Barr virus‐encoded small RNAs, it lacked expression of all examined NKR. G, Monomorphic epitheliotropic intestinal T‐cell lymphoma case (UPN \#19). This case showed expression of LILRB1, NKp46 and NKG2D, but not DNAM1. H, Aggressive NK‐cell leukemia case (UPN \#22). This case was positive for all examined NKR](CAS-109-1254-g001){#cas13512-fig-0001}

![Dendritic cells and endothelial cells in follicular helper T‐cell‐type peripheral T‐cell lymphoma cases expressed DNAM1. A, Although the lymphoma cells were negative for DNAM1, dendritic cells and endothelial cells were positive for this molecule as shown by red arrowheads (unique patient number \[UPN\] \#3). DNAM1 was more weakly stained in dendritic cells than in endothelial cells. B, As shown by red arrowheads, DNAM1 was clearly detected in endothelial cells in DNAM1‐negative case (UPN \#7)](CAS-109-1254-g002){#cas13512-fig-0002}

3.3. Clinical features and outcomes of examined cases {#cas13512-sec-0010}
-----------------------------------------------------

Median age at diagnosis was 64.5 years (range, 21‐82), and the male/female ratio was 3.5. As an initial involved site, nodal and extranodal presentations were observed in 10 (45%) and 12 (55%) cases, respectively. Six cases (27%) showed limited‐stage disease. According to the IPI score, low, low‐intermediate, high‐intermediate, and high‐risk categories were determined in 2 (9%), 7 (32%), 8 (36%), and 5 cases (23%), respectively. Thirteen of 19 treated cases (68%) received CHOP‐like chemotherapy regimen. Median follow‐up duration was 20.4 months (range, 0.6‐63.9), and the median OS for the entire group was 28.3 months (95% CI 4.4, NA) (Figure [3](#cas13512-fig-0003){ref-type="fig"}A). Although there was no significant difference in the OS by age ≥60 years (log‐rank test, *P* = .796), IPI high‐risk group (log‐rank test, *P* \< .001) had a negative impact on the OS (Figure [3](#cas13512-fig-0003){ref-type="fig"}B). Expressions of LILRB1 (log‐rank test, *P* = .796), DNAM1 (log‐rank test, *P* = .655), and NKp46 (log‐rank test, *P* = .508) showed no adverse effect on the OS (Figure [3](#cas13512-fig-0003){ref-type="fig"}C‐E), whereas the expression of NKG2D (log‐rank test, *P* = .024) had a negative impact on the OS (Figure [3](#cas13512-fig-0003){ref-type="fig"}F).

![Clinical outcomes of the examined 22 cases. A, Overall survival (OS) of the 22 examined cases. Median survival duration was estimated as 28.3 months. B, Although age ≥60 years was not associated with OS, high‐risk group of international prognostic index (IPI) showed a negative impact on the OS (log‐rank test, *P* \< .001). C‐F, Expression of natural killer (NK) cell receptors (NKR) and OS. Although the expression of (C) leukocyte immunoglobulin‐like receptor subfamily B member 1 (LILRB1), (D) DNAM1, and (E) NKp46 had no impact on the OS, expression of (F) NKG2D showed an adverse effect on the OS (log‐rank test, *P* = .024)](CAS-109-1254-g003){#cas13512-fig-0003}

4. DISCUSSION {#cas13512-sec-0011}
=============

In the present study, we confirmed the expression of LILRB1, DNAM1, NKp46 and NKG2D in some PTNKL entities. Although LILRB1 expression had not yet been evaluated in NK‐cell malignancies, we verified the presence in ANKL and ENKL, and further found that the expression pattern was not disease‐specific. Previous reports showed that LILRB1 was expressed not only in Sézary cells, but also in B‐cell lines.[15](#cas13512-bib-0015){ref-type="ref"}, [16](#cas13512-bib-0016){ref-type="ref"} In addition, the stimulation was shown to suppress the proliferation in spite of the different cell lineage.[15](#cas13512-bib-0015){ref-type="ref"}, [16](#cas13512-bib-0016){ref-type="ref"} The frequent expression of LILRB1 suggests that this molecule may have a potential to mediate growth‐inhibitory signals in PTNKL cells. Our observation raises the possibility that LILRB1 might be a novel therapeutic target for PTNKL.

Compared with LILRB1, the expression of activating NKR was relatively restricted to CM‐positive neoplasms. Although NKp46 and NKG2D were detected mainly in neoplastic cells, DNAM1 was also expressed in the surrounding reticuloendothelial cells. Increased expression levels of DNAM1 were observed in inflammatory monocytes and activated endothelial cells.[17](#cas13512-bib-0017){ref-type="ref"}, [18](#cas13512-bib-0018){ref-type="ref"} The enhanced expression of DNAM1 likely leads to acceleration of cell adhesion in the expressing cells.[17](#cas13512-bib-0017){ref-type="ref"}, [18](#cas13512-bib-0018){ref-type="ref"} This molecule may function in cell‐cell interactions in addition to its cytotoxic effects in the tumor environment. Recent study showed that NKp46 was detected in ALK^+^ ALCL cells but not in EATL cells.[12](#cas13512-bib-0012){ref-type="ref"} Nevertheless, we observed that NKp46 was detected in some of the surrounding bystander cells but not in ALK^+^ ALCL cells (Figure [1](#cas13512-fig-0001){ref-type="fig"}C). Although MEITL had been included in EATL in the previous WHO classification, our three MEITL cases (two αβT‐cell and one γδT‐cell types) were all positive for NKp46. Our observations show that the expression of NKp46 and NKG2D is a hallmark of lymphomas derived from NK cells and unconventional innate‐like T cells. Although aberrant expression might occur in neoplastic cells, the presence of the activating NKR on non‐γδT‐cell lymphoma cells may mirror the acquisition of its natural cytotoxic function. Therefore, even though the lymphoma cells are infected with EBV, non‐γδT‐cell type CTL‐derived lymphomas lacking the expression of activating NKR should be distinguished from ENKL.

Although several problems such as sensitivity of IHC and loss of expression remain, NKG2D was not so frequently expressed in CM‐positive neoplasms. Expression levels of NKG2D in NK cells are likely increased through STAT3 activation, which is considered one of the important alterations in PTNKL.[19](#cas13512-bib-0019){ref-type="ref"}, [20](#cas13512-bib-0020){ref-type="ref"} Previous study indicated that approximately 30% of cases of ENKL presented STAT3 phosphorylation.[21](#cas13512-bib-0021){ref-type="ref"} In addition, the activation of STAT3 seems to be associated with a poor clinical outcome in ENKL.[22](#cas13512-bib-0022){ref-type="ref"} Our result may imply that the detection of NKG2D had selected higher risk cases among the patients with relatively poor prognostic diseases such as ANKL, ENKL, and MEITL. Although it is difficult to draw a conclusion as a result of the small numbers of cases, the innate lymphoid cell‐associated marker might show an impact on clinical outcome when such standard regimens are adopted.

In summary, we showed, for the first time, that DNAM1 and NKG2D are expressed in aggressive PTNKL. Although we failed to discriminate between T‐ and NK‐cell neoplasms by recognition of the expression profile of NKR in PTNKL, the detection of activating NKR including DNAM1, NKp46, and NKG2D characterizes CM‐positive PTNKL as neoplasms derived from NK cells and unconventional innate‐like T cells. We propose that the presence of the activating NKR may provide new insights into the understanding of ENKL‐like T‐cell lymphomas. Further studies are needed to determine whether the expression of activating NKR delineates the biologically and clinically distinct groups of PTNKL and to relate them to the pathogenesis.
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